What's The Future of Cancer Immunotherapy? World Renowned Cancer Expert Shares His Perspective

curncman
Posts: 432
Joined: Fri Jun 26, 2020 8:27 am

Immunotherapy for treating multiple myeloma

Post by curncman »

Immunotherapy for treating multiple myeloma

curncman
Posts: 432
Joined: Fri Jun 26, 2020 8:27 am

Antibody-drug conjugates targeting CD45 plus Janus kinase inhibitors effectively condition for allogeneic hematopoietic

Post by curncman »

Antibody-drug conjugates targeting CD45 plus Janus kinase inhibitors effectively condition for allogeneic hematopoietic stem cell transplantation

https://www.researchgate.net/publicatio ... plantation
curncman
Posts: 432
Joined: Fri Jun 26, 2020 8:27 am

Lineage Cell, Cancer Research U.K. advance cancer vaccine

Post by curncman »

Lineage Cell, Cancer Research U.K. advance cancer vaccine

https://www.scienceboard.net/index.aspx ... temID=1489

October 13, 2020 -- Lineage Cell Therapeutics and partner Cancer Research U.K. have posted positive preliminary phase I results from an ongoing study of VAC2 in non-small cell lung cancer (NSCLC).

In the study, VAC2 potently induced immune responses with high levels of peripheral antigen-specific responses and peripheral antigen-specific immunogenicity in all patients. Based on these results, the company will seek to evaluate VAC2 in combination with other therapies such as chemotherapy and programmed cell death-1 (PD-1) immunotherapy. The vaccine appears to be well-tolerated with no unexpected adverse events.

VAC2 is an allogeneic, off-the-shelf cancer vaccine product candidate designed to stimulate patient immune responses to an antigen commonly expressed in cancerous cells but not in normal adult cells. VAC2 is produced via a pluripotent cell technology platform that uses directed differentiation to nonproliferating mature dendritic cells, the most potent antigen-presenting cells in the body. The VAC technology platform can be modified to carry any antigen, including patient-specific tumor neoantigens or viral antigens.

Recently, Lineage exercised its option to acquire data from Cancer Research U.K. and assumed responsibility for further development and future opportunities derived from the VAC platform. Cancer Research U.K.'s Centre for Drug Development will conclude the ongoing clinical trial.
curncman
Posts: 432
Joined: Fri Jun 26, 2020 8:27 am

Cancer Immunotherapy 101 with Dr. E. John Wherry

Post by curncman »

Cancer Immunotherapy 101 with Dr. E. John Wherry


curncman
Posts: 432
Joined: Fri Jun 26, 2020 8:27 am

Rubius Therapeutics Announces Preclinical Data Supporting its Lead Clinical Oncology Program, RTX-240, to be Presented a

Post by curncman »

Rubius Therapeutics Announces Preclinical Data Supporting its Lead Clinical Oncology Program, RTX-240, to be Presented at the Society for Immunotherapy of Cancer’s Annual Meeting
October 15, 2020 8:00 AM
CAMBRIDGE, Mass., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that the company will present preclinical data supporting its lead clinical oncology program, RTX-240, at the upcoming Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting. The meeting is being held virtually from November 9-14, 2020. RTX-240 is an allogeneic, off-the-shelf Red Cell Therapeutic™ that is engineered to mimic the human immune system by stimulating adaptive and innate immunity to generate an anti-tumor immune response.

“At SITC, we plan to present preclinical data supporting our lead clinical oncology program, RTX-240, demonstrating that RTX-240 promotes T cell and NK cell activation and expansion in vitro and in vivo,” said Laurence Turka, M.D., chief scientific officer of Rubius Therapeutics. “We are continuing to enroll patients in the Phase 1/2 clinical trial of RTX-240 for the treatment of patients with relapsed/refractory or locally advanced solid tumors, and we have a cleared Investigational New Drug application for the treatment of patients with relapsed/refractory acute myeloid leukemia for which we are actively recruiting patients.”
curncman
Posts: 432
Joined: Fri Jun 26, 2020 8:27 am

Personalised interception of autoimmune diseases: Immunopathogenesis, trials and implementation

Post by curncman »

Personalised interception of autoimmune diseases: Immunopathogenesis, trials and implementation

https://www.immunology.org/events/perso ... ementation

GoToWebinar
Tuesday, 27 October, 2020 - 11:00 to 11:45


This webinar from our Regional & Affinity Group series is brought to you by the BSI West of Scotland Immunology Group. This session will be presented by Professor Ranjeny Thomas and will take place on Tuesday 27 October, 11:00 to 11:45 BST.

Autoimmune diseases, including rheumatoid arthritis and type 1 diabetes, develop and persist due to the failure of immune self-tolerance. Patients rarely achieve drug-free remission after diagnosis, and although at-risk individuals can be identified, disease cannot yet be successfully intercepted. Precision medicine is increasingly offering solutions to diseases that have been incurable. This talk examines progress in the field of antigen-specific immunotherapy for interception and control of autoimmune disease.

Speaker: Professor Ranjeny Thomas, Professor of Rheumatology, University of Queensland

Professor Thomas is Professor of Rheumatology at University of Queensland, Translational Research Institute, consultant rheumatologist at Princess Alexandra Hospital, fellow of the Australian Academy of Health and Medical Sciences and Chief Technical Officer of the Uniquest spin-off company Dendright. In the recent Queen’s Birthday Honours, she was awarded member of the Order of Australia.

Her research seeks to understand autoimmune disease and restoration of immune tolerance. Through this work, she developed dendritic cell-based antigen-specific immunotherapy in the first proof-of-concept trial in Rheumatoid Arthritis. She developed a liposome immunotherapy that targets dendritic cells to induce antigen-specific tolerance. The product, DEN181, was developed by Dendright, in partnership with Janssen-Biotech, the US pharmaceutical subsidiary of Johnson and Johnson, and tested in a phase 1b clinical trial in RA. Her team recently partnered with CSL to develop immunotherapy for Sjogren’s syndrome. Thomas is progressing the development of liposome-based tolerance strategies in autoimmune diseases, as well as nanoparticle-based dendritic cell targeted cancer vaccines. She has contributed major insights into how the microbiome is involved in causing spondyloarthropathy, leading to the development of disease biomarkers and therapeutic strategies.

This webinar is free for all BSI members. Non-members will be charged £10. You can join the BSI online - membership provides many benefits to help you progress your career. Undergraduate membership is free.
curncman
Posts: 432
Joined: Fri Jun 26, 2020 8:27 am

Selective tumor antigen vaccine delivery to human CD169+ antigen-presenting cells using ganglioside-liposomes [Immunolog

Post by curncman »

Selective tumor antigen vaccine delivery to human CD169+ antigen-presenting cells using ganglioside-liposomes [Immunology and Inflammation]

https://www.x-mol.com/paper/1317594922755526656

Proceedings of the National Academy of Sciences of the United States of America ( IF 9.412 ) Pub Date : 2020-10-16 , DOI: 10.1073/pnas.2006186117
Alsya J. Affandi, Joanna Grabowska, Katarzyna Olesek, Miguel Lopez Venegas, Arnaud Barbaria, Ernesto Rodríguez, Patrick P. G. Mulder, Helen J. Pijffers, Martino Ambrosini, Hakan Kalay, Tom O’Toole, Eline S. Zwart, Geert Kazemier, Kamran Nazmi, Floris J. Bikker, Johannes Stöckl, Alfons J. M. van den Eertwegh, Tanja D. de Gruijl, Gert Storm, Yvette van Kooyk, Joke M. M. den Haan

Priming of CD8+ T cells by dendritic cells (DCs) is crucial for the generation of effective antitumor immune responses. Here, we describe a liposomal vaccine carrier that delivers tumor antigens to human CD169/Siglec-1+ antigen-presenting cells using gangliosides as targeting ligands. Ganglioside-liposomes specifically bound to CD169 and were internalized by in vitro-generated monocyte-derived DCs (moDCs) and macrophages and by ex vivo-isolated splenic macrophages in a CD169-dependent manner. In blood, high-dimensional reduction analysis revealed that ganglioside-liposomes specifically targeted CD14+ CD169+ monocytes and Axl+ CD169+ DCs. Liposomal codelivery of tumor antigen and Toll-like receptor ligand to CD169+ moDCs and Axl+ CD169+ DCs led to cytokine production and robust cross-presentation and activation of tumor antigen-specific CD8+ T cells. Finally, Axl+ CD169+ DCs were present in cancer patients and efficiently captured ganglioside-liposomes. Our findings demonstrate a nanovaccine platform targeting CD169+ DCs to drive antitumor T cell responses.
curncman
Posts: 432
Joined: Fri Jun 26, 2020 8:27 am

Unraveling Antigenic Cross-Presentation

Post by curncman »

Unraveling Antigenic Cross-Presentation

curncman
Posts: 432
Joined: Fri Jun 26, 2020 8:27 am

Cancer Stem Cells with Sandra Dillon, Tannishtha Reya, Rob Signer, and Karen Aboody

Post by curncman »

Cancer Stem Cells with Sandra Dillon, Tannishtha Reya, Rob Signer, and Karen Aboody

Post Reply